Soleno Therapeutics, a Neurocrine Biosciences company, develops therapies for rare genetic disorders. The first and only therapy for the treatment of hyperphagia in #PraderWilliSyndrome received full FDA-approval in March 2025.
C-US-PWS-00066
Shared 1 year ago
3.7K views
Shared 1 year ago
201 views
Shared 1 year ago
85 views
Shared 1 year ago
148 views
Shared 1 year ago
3.1K views
Shared 1 year ago
412 views
Shared 2 years ago
837 views
Shared 2 years ago
278 views